{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:10:36Z","timestamp":1791166236819,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T00:00:00Z","timestamp":1475539200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_12001\/2"],"award-info":[{"award-number":["MC_PC_12001\/2"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thegreenjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.radonc.2016.08.011","type":"journal-article","created":{"date-parts":[[2016,9,3]],"date-time":"2016-09-03T00:15:02Z","timestamp":1472861702000},"page":"92-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Quantifying target-specific motion in anal cancer patients treated with intensity modulated radiotherapy (IMRT)"],"prefix":"10.1016","volume":"121","clinical-trial-number":[{"clinical-trial-number":"isrctn88455282","registry":"10.18810\/isrctn"}],"author":[{"given":"Lisa","family":"Durrant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Muirhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2016.08.011_b0005","doi-asserted-by":"crossref","first-page":"v87","DOI":"10.1093\/annonc\/mdq171","article-title":"Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Glynne-Jones R, Northover JM, Cervantes A, Group EGW","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2016.08.011_b0010","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00d72 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2016.08.011_b0015","unstructured":"NIH National Cancer Institute Surveillance, Epidemiology, and End Results Program 2000 [Online] Available at: <http:\/\/seercancergov\/statfacts\/html\/anushtml> [accessed 16.02.16]."},{"key":"10.1016\/j.radonc.2016.08.011_b0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.011_b0025","series-title":"Report 83: prescribing, recording and reporting photon beam intensity-modulated radiation therapy (IMRT)","author":"ICRU","year":"2010"},{"key":"10.1016\/j.radonc.2016.08.011_b0030","series-title":"Report 50: prescribing, recording and reporting photon beam therapy","author":"ICRU","year":"1993"},{"key":"10.1016\/j.radonc.2016.08.011_b0035","series-title":"Report 62: Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50)","author":"ICRU","year":"1999"},{"key":"10.1016\/j.radonc.2016.08.011_b0040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0167-8140(02)00015-4","article-title":"Margins for geometric uncertainty around organs at risk in radiotherapy","volume":"62","author":"McKenzie","year":"2002","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.011_b0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0167-8140(02)00140-8","article-title":"Geometrical uncertainties, radiotherapy planning margins, and the ICRU-62 report","volume":"64","author":"Stroom","year":"2002","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.011_b0050","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.radonc.2014.05.013","article-title":"Position shifts and volume changes of pelvic and para-aortic nodes during IMRT for patients with cervical cancer","volume":"111","author":"Schippers","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.011_b0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1748-717X-5-53","article-title":"Independent position correction on tumor and lymph nodes; consequences for bladder cancer irradiation with two combined IMRT plans","volume":"5","author":"van Rooijen","year":"2010","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2016.08.011_b0060","doi-asserted-by":"crossref","first-page":"20130696","DOI":"10.1259\/bjr.20130696","article-title":"Intensity-modulated radiotherapy (IMRT) to prostate and pelvic nodes-is pelvic lymph node coverage adequate with fiducial-based image-guided radiotherapy?","volume":"87","author":"Eminowicz","year":"2014","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2016.08.011_b0065","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3109\/0284186X.2011.590522","article-title":"Plan robustness of simultaneous integrated boost radiotherapy of prostate and lymph nodes for different image-guidance and delivery techniques","volume":"50","author":"Thornqvist","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2016.08.011_b0070","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijrobp.2011.10.068","article-title":"Setup variations in radiotherapy of anal cancer: advantages of target volume reduction using image-guided radiation treatment","volume":"84","author":"Chen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.011_b0075","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.radonc.2015.09.009","article-title":"Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer","volume":"117","author":"Robinson","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.011_b0080","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ijrobp.2008.12.082","article-title":"Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma","volume":"75","author":"Aizer","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.011_b0085","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ijrobp.2007.04.003","article-title":"An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94\u201313, with emphasis on unexpected hormone\/radiation interactions","volume":"69","author":"Lawton","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.011_b0090","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.ijrobp.2011.02.010","article-title":"Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study)","volume":"82","author":"Ortholan","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.011_b0095","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1002\/cncr.28849","article-title":"Complications of pelvic radiation in patients treated for gynecologic malignancies","volume":"120","author":"Viswanathan","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2016.08.011_b0100","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/DCR.0b013e3182a226bd","article-title":"Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with our without chemotherapy","volume":"56","author":"Doyen","year":"2013","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.radonc.2016.08.011_b0105","unstructured":"Muirhead R, Adams R, Gilbert D, Harrison M, Glynne-Jones R, Sebag-Montefiore D, et al. National guidance for IMRT in anal cancer. 2015 [Online] Available at: <www.analimrtguidance.co.uk>; 2015 [accessed 16.02.16]."},{"key":"10.1016\/j.radonc.2016.08.011_b0110","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.clon.2014.08.001","article-title":"Anal cancer: developing an intensity-modulated radiotherapy solution for ACT2 fractionation","volume":"26","author":"Muirhead","year":"2014","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2016.08.011_b0115","unstructured":"The Royal College of Radiologists, Institute of Physics and Engineering in Medicine, Society and College of Radiographers. On target: ensuring geometric accuracy in radiotherapy. 2008 [Online] Available at: <https:\/\/www.ipem.ac.uk\/Portals\/0\/Images\/On%20target%20ensuring%20geometric%20accuracy%20in%20radiotherapy.pdf> [accessed 15.03.16]."},{"key":"10.1016\/j.radonc.2016.08.011_b0120","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0360-3016(00)00518-6","article-title":"The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy","volume":"47","author":"van Herk","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.011_b0125","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1118\/1.3480505","article-title":"Comparison of three strategies in management of independent movement of the prostate and pelvic lymph nodes","volume":"37","author":"Xia","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2016.08.011_b0130","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1118\/1.2804579","article-title":"An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodes","volume":"34","author":"Ludlum","year":"2007","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2016.08.011_b0135","first-page":"3371","article-title":"Cone beam CT pre- and post-daily treatment for assessing geometrical and dosimetric intrafraction variability during radiotherapy of prostate cancer","volume":"12","author":"Reggiori","year":"2010","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.radonc.2016.08.011_b0140","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.radonc.2012.06.013","article-title":"Recommendations for CTV margins in radiotherapy planning for non melanoma skin cancer","volume":"104","author":"Khan","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.011_b0145","unstructured":"Radiation Therapy Oncology Group, RTOG 0529, Protocol Information. A Phase II Evaluation of Dose-Painted IMRT in Combination with 5-Fluorouracil and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal; 2011 [Online] Available at: https:\/\/www.rtog.org\/ClinicalTrials\/ProtocolTable\/StudyDetails.aspx?study=0529 [accessed 01.08.16]."},{"key":"10.1016\/j.radonc.2016.08.011_b0150","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ijrobp.2011.12.058","article-title":"Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer","volume":"83","author":"Ng","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.08.011_b0155","doi-asserted-by":"crossref","first-page":"10688","DOI":"10.3748\/wjg.v21.i37.10688","article-title":"Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity","volume":"21","author":"Belgioia","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.radonc.2016.08.011_b0160","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.radonc.2009.07.006","article-title":"A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy","volume":"93","author":"Devisetty","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.011_b0165","article-title":"Intensity-modulated radiation therapy for anal cancer: results from a multi-institutional retrospective cohort study","author":"Call","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2016.08.011_b0170","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.radonc.2015.08.008","article-title":"Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer","volume":"117","author":"Joseph","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.08.011_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2016.06.260","article-title":"Stepwise multi-centre introduction of IMRT for anal cancer in the UK: from consensus guidance to large-scale prospective audit, prior to future clinical trials","author":"Gilbert","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814016342542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814016342542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T20:59:20Z","timestamp":1536440360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814016342542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0167814016342542"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2016.08.011","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantifying target-specific motion in anal cancer patients treated with intensity modulated radiotherapy (IMRT)","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2016.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}